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Introduction
============

Oxysterol binding proteins (OSBPs)[\*](#fn1){ref-type="fn"} define a large protein family whose members are found in mammals ([@bib13]), *Drosophila* ([@bib1]), *C. elegans* ([@bib6]), and yeast ([@bib24]; [@bib15]; [@bib4]). Initial studies suggested that OSBPs mediate the potent downregulation of sterol biosynthesis by oxysterols ([@bib44]; [@bib13]). Although evidence consistent with this hypothesis was culled from genetic experiments in yeast and mammalian cells ([@bib24]; [@bib28]; [@bib4]), other evidence indicates that OSBPs are not direct mediators of oxysterol signaling ([@bib5]). Rather, these proteins have other functions that interface with membrane trafficking from the Golgi complex ([@bib15]), progression of cells through the cell cycle ([@bib1]), and tumor metastasis ([@bib18]).

Yeast express seven OSBPs. Three (Osh1p, Osh2p, and Osh3p) are classified as long OSBPs, typified by the mammalian OXYB, where a large extension is found NH~2~-terminal to the 430 amino acid oxysterol binding homology domain ([Fig. 1](#fig1){ref-type="fig"} A). The remaining four are homologous to the oxysterol binding domain of OXYB and are classified as short OSBPs ([Fig. 1](#fig1){ref-type="fig"} A). None of the yeast OSBPs individually plays an essential function, but deletion of all seven OSBP genes results in inviability ([@bib24]; [@bib15]; [@bib30]; [@bib4]).

###### 

**Kes1p function and the Sec14p pathway.** (A) The yeast OSBP family. The general organization of the seven yeast OSBP family members is given and compared with the human OSBP (hOSBP). Yeast proteins are identified at left by their common designations (see [@bib4]). Regions homologous to the oxysterol binding domain of hOSBP are shown in black, and the primary sequence identities within that region are given. The three long yeast OSBPs (Osh1p, Osh2p and Osh3p) share homologies at their COOH-terminal domains with hOSBP (stippled areas), whereas these particular homologies are present in the four short yeast OSBPs (Kes1p, Hes1p, Osh6, and Osh7). Ultimate residues for each protein are numbered at right. (B) Pathway for Sec14p-dependent Golgi secretory function. Roles for phosphatidylcholine (PC), DAG, PA, PI(4)P, and PI(4,5)P~2~ in stimulating yeast Golgi complex secretory function have been proposed. PC, DAG, and PA are proposed to mediate combinatorial regulation of a pair of imperfectly redundant ARFGAPs (Gcs1p and Age2p) whose activity is required for Sec14p pathway function (Yanagisawa, L., and V.A. Bankaitus, unpublished data). The known execution points for relevant genes whose inactivation effects "bypass Sec14p" (i.e., *CKI1*, *PCT1*, *CPT1*, and *SAC1*) are shown. The execution point of the *KES1* gene product in the Sec14p pathway is unknown.
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Sec14p is the major yeast PI/PC-transfer protein (PITP) ([@bib3]; [@bib26]; [@bib32]). Analyses of mutations that allow yeast to grow in the absence of the essential Sec14p (i.e., 'bypass Sec14p' mutations) demonstrate that Sec14p regulates lipid metabolism so that a permissive membrane environment for Golgi complex secretory function is maintained ([Fig. 1](#fig1){ref-type="fig"} B; [@bib10],[@bib11]; [@bib33]; [@bib22]; [@bib32]; [@bib47]). An important component of this Sec14p-mediated regulation of lipid metabolism appears to involve stimulation of the adenosine diphosphate-ribosylation factor guanosine triphosphatase activating protein (ARFGAP) activities of the yeast *GCS1* and *AGE2* gene products (Yanagisawa, L., and V.A. Bankaitus, unpublished data). In this fashion, Sec14p may impose a trans-Golgi region--specific regulation of the adenosine diphosphate-ribosylation factor (ARF) GTPase cycle in yeast. A functional relationship between Sec14p and OSBP function in yeast became apparent when it was discovered that inactivation of the *KES1* gene, which encodes one of the short OSBP family members, uniquely elicits a "bypass Sec14p" phenotype ([@bib15]). No other individual yeast OSBP defect elicits "bypass Sec14p" ([@bib15]; [@bib4]). This "bypass Sec14p" phenotype makes it possible to dissect the various functional properties of Kes1p.

Herein, we demonstrate that yeast Kes1p is a phosphoinositide (PIP) binding protein whose lipid binding activities are necessary, but not sufficient, for Kes1p localization to yeast Golgi membranes. We also show that Golgi complex localization is critical for Kes1p function. Finally, we present evidence to suggest that Kes1p activity influences ARF function in yeast. The collective data suggest that OSBPs are compartment specific regulators (or effectors) of ARF function in eukaryotes.

Results
=======

Kes1p functional domains
------------------------

We independently recovered 51 *kes1* loss-of-function mutations in a "bypass Sec14p" mutant screen ([@bib11]; [@bib15]). Of these, nine sustain wild-type levels of Kes1p. Gap repair experiments, coupled with DNA sequence determinations, revealed these nine mutations define six alleles ([Fig. 2](#fig2){ref-type="fig"} A). Four represent a GAA → AA mutation that substitutes lysine for glutamate at Kes1p residue 312 (E312K). One represents a double mutation that converts codons 201 and 202 from TTGCAT to TTCAAT, and substitutes phenylalanine-asparagine for leucine-histidine (LH20/202FN).

###### 

**Kes1p functional domains.** (A) Kes1p domain structure. The 434-residue Kes1p sequence is represented with the OSBP and PH domains identified by stippled boxes as indicated at top. The six *kes1* inactivating mutations of interest are identified at bottom, and the individual sites of missense substitution relative to the Kes1p primary sequence representation are indicated by the black lines. (B) Kes1p PH domain. The primary sequence of the Kes1p PH domain is aligned other known PH domains (from [@bib29]). A secondary structure diagram derived from the PLC-δ1 PH domain crystal structure is given at top. The signature tryptophan of PH domains is boxed (W~317~ for Kes1p). Basic residues (i.e., R~236~, K~242~, and K~243~) in the predicted variable loop 2 (VL-2) of Kes1p that likely form the inositide binding motif are identified (solid circles). (C) OSBP domains from the yeast OSBPs and hOSBP are aligned. The canonical OSBP domain consists of two conserved motifs (identified by black bars at top) separated by linkers of 13--20 amino acids.
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The sequences surrounding P30T, S43Y, and LH201/202FN revealed no informative homologies. However, clues were gleaned from regions surrounding the E312K, E107K, and K109A substitutions. E312K lies within a domain that exhibits features of Pleckstrin homology (PH) domains. Although this region is not scored as a PH domain by various search programs, it includes the signature invariant tryptophan (W317) that is positioned ∼100 residues downstream of a GIL motif (Kes1p residues 205--207). PH domains are often bounded by a GXL motif at the NH~2~ terminus, and the signature tryptophan is positioned ∼110 residues downstream of that motif ([@bib29]). Alignment of the putative Kes1p PH domain (residues 180--330) with known PH domains is shown ([Fig. 2](#fig2){ref-type="fig"} B). Although proof that this domain conforms to the PH domain fold awaits structural analyses, for purposes of convenience we will refer to this domain as the Kes1p PH domain.

BLAST analyses also identify a motif (Kes1p residues 108--149) that is present only in OSBPs and is highly conserved among them ([Fig. 2](#fig2){ref-type="fig"} C). This OSBP domain consists of two 11-residue motifs separated by a linker of ∼20 divergent residues. Two of the *kes1* alleles alter residues adjacent to (E107K), or within (H143Y), this domain.

Kes1p is a PIP binding protein
------------------------------

As PI(4,5)P~2~ and other PIPs are common ligands for PH domains, we assessed binding of purified Kes1p to PI(4,5)P~2~ or its soluble headgroup inositol-1,4,5-trisphosphate (IP~3~). To this end, \[^3^H\]-BZDC-PI(4,5)P~2~ and \[^3^H\]-BZDC-IP~3~ were used as photo-affinity ligands ([@bib14]; [@bib37]; [@bib38]; [@bib7],[@bib8]; [@bib16]). The \[^3^H\]-BZDC-PI(4,5)P~2~ binding experiments were performed in a mixed micelle system where the photo-affinity ligand was a trace component. Thus, the photolabeling assay requires Kes1p to interact with photo probe monomers in the face of large detergent excess. Although Sec14p fails to bind either probe (unpublished data), Kes1p binds both \[^3^H\]-BZDC-PI(4,5)P~2~ and \[^3^H\]-BZDC-IP~3~ avidly, as indicated by recovery of appropriate covalent adducts ([Fig. 3](#fig3){ref-type="fig"} A). The intensities of Kes1p photolabeling were similar to those scored for the PIP binding protein gelsolin.

###### 

**Kes1p binds PIPs.** (A) Photo-cross-linking of Kes1p to \[^3^H\]BZDC-PI(4,5)P~2~ and \[^3^H\]BZDC-IP~3~. Purified recombinant Kes1p was incubated with \[^3^H\]BZDC-PI(4,5)P~2~ photo-probe in a mixed micelle system, the reaction was irradiated under long wave UV light, and covalent adducts were resolved by SDS-PAGE and autoradiography. In the left panels, a representative autoradiogram is shown with a corresponding densitometric quantification of photo-cross-linking provided below. A reaction of Kes1p and \[^3^H\]BZDC-PI(4,5)P~2~ with no competitor yields the total photolabeling lane (T). Addition of excess competitor PI(4,5)P~2~ (10 μM) or 0.1 mM or 1 mM IP~3~, as indicated in the competition (C) lanes, displaces photo-probe from Kes1p and reduces photolabeling. In the right panel, a representative autoradiogram is shown from a Kes1p/\[^3^H\]BZDC-IP~3~ photolabeling reaction with no competitor IP~3~ (T) or with excess competitor IP~3~ (C). Purified gelsolin (gift from Paul Janmey, Harvard Medical School, Cambridge, MA) was employed as a positive control. Purified Sec14p fails to bind photo-probe and served as negative control (unpublished data). (B) Concentration-dependent displacement of photo-probe from Kes1p by PI(4,5)P~2~. Purified Kes1p was incubated in a series of mixed micelle photolabeling reactions supplemented with increasing concentrations of PI(4,5)P~2~. Efficiency of photolabeling was determined by densitometric scanning of autoradiograms, and is plotted as a function of the log~10~ of the competitor PI(4,5)P~2~ concentration. (C) Kes1p PH domain is sufficient for PIP binding. Purified recombinant Kes1p and Kes1p PH domain were incorporated into reactions using \[^3^H\]BZDC-PI(4,5)P~2~ as photo-probe. Total (T) and competition (C) reactions are as above. (D) Kes1p has weak affinity for other acidic phospholipids. Kes1p was incorporated into a standard mixed micelle photolabeling reaction using \[^3^H\]BZDC-PI(4,5)P~2~ as photo-probe. Reactions with no competitor (Total), and with competitor lipids (10 μM final concentration; indicated at top), are shown. PIP, phosphatidylinositol-4-P; PI, phosphatidylinositol; PE; phosphatidylethanolamine; PS, phosphatidylserine; DiC8, di-C8:0 diacylglycerol.
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Kes1p-\[^3^H\]-BZDC-IP~3~ solution binding experiments also impose rigorous constraints on binding. Both photo-probes are displaced from Kes1p by challenge with excess unlabeled PI(4,5)P~2~ or IP~3~ competitor. However, an 83-fold molar excess of unlabeled PI(4,5)P~2~ displaces both photo-probes, whereas a 10^3^-fold molar excess of IP~3~ is required for displacement of \[^3^H\]-BZDC-PI(4,5)P~2~ ([Fig. 3](#fig3){ref-type="fig"} A). These data suggest that Kes1p has a 10-fold higher affinity for PI(4,5)P~2~ than it does for IP~3~.

To quantify Kes1p affinity for PI(4,5)P~2~, we determined the concentration of competitor required for 50% displacement of \[^3^H\]BZDC-PI(4,5)P~2~ from Kes1p (IC~50~). Although photoaffinity labeling is a nonequilibrium process ([@bib14]) and cannot directly give equilibrium dissociation constants, displacement by competing ligands yields a rank order of relative affinities. A dose-dependent reduction in photolabeling efficiency was observed when PI(4,5)P~2~ was employed as competitor ([Fig. 3](#fig3){ref-type="fig"} B). The IC~50~ for PI(4,5)P~2~ is 1.9 μM with an estimated *K* ~D~ = 2.5 μM for Kes1p-\[^3^H\]BZDC-PI(4,5)P~2~ binding. These values resemble those measured for PI(4,5)P~2~ and \[^3^H\]BZDC-PI(4,5)P~2~ binding by PLC-δ1 ([@bib43]; [@bib29]).

Kes1p PH domain is sufficient for PIP binding
---------------------------------------------

We tested whether the Kes1p PH domain represents the PI(4,5)P~2~ and IP~3~ binding module. Indeed, a 144 amino acid Kes1p fragment that consists largely of the PH domain (residues 171--314) is sufficient for PI(4,5)P~2~ and IP~3~ binding ([Fig. 3](#fig3){ref-type="fig"} C). A 110 amino acid region of Kes1p (residues 205--314) that defines the putative Kes1p PH domain ([Fig. 2](#fig2){ref-type="fig"} B) also binds IP~3~ photo-probe (unpublished data). Neither a smaller region of Kes1p (residues 205--309) that fully overlaps this domain, nor a Kes1p domain (residues 220--330) that incompletely overlaps this domain exhibits any inositide binding activity (unpublished data). Interestingly, the minimum Kes1p inositide binding module does not include W317, the signature residue of PH domains ([Fig. 2](#fig2){ref-type="fig"} B; see below).

Specificity of PIP binding
--------------------------

To characterize specificity of Kes1p binding to PIPs, we employed a competitive displacement strategy using a variety of binding substrates in a Kes1p-\[^3^H\]BZDC-PI(4,5)P~2~ photolabeling assay. At 400-fold molar excess, all PIPs tested and other acidic phospholipids (phosphatidylserine, phosphatidic acid, and cardiolipin) displaced \[^3^H\]BZDC-PI(4,5)P~2~ ([Fig. 3](#fig3){ref-type="fig"} D). Other lipids (phosphatidylethanolamine, phosphatidylcholine, ceramide, and diacylglycerol) were ineffective. Soluble inositol-polyphosphates (IP~3~, IP~4~, IP~6~) also failed to displace \[^3^H\]BZDC-PI(4,5)P~2~ from Kes1p (unpublished data). When unlabeled competitor lipids were reduced to a 10-fold molar excess relative to \[^3^H\]BZDC-PI(4,5)P~2~, only PI(4,5)P~2~ displaced photo-probe. PI, PI(4)P, phosphatidic acid (PA), and other acidic phospholipids were ineffective (unpublished data). A 10-fold molar excess of PI(3,4,5)P~3~, PI(3,4)P~2~, or PI(3,5)P~2~ also failed to displace \[^3^H\]BZDC-PI(4,5)P~2~ ([Fig. 3](#fig3){ref-type="fig"} D). Thus, PI(4,5)P~2~ is the preferred Kes1p ligand in vitro.

Mutations in the Kes1p PH domain influence PIP binding
------------------------------------------------------

Since the Kes1p PH domain binds PI(4,5)P~2~, we investigated whether integrity of this domain is required for PIP binding. To this end, we characterized the binding properties of Kes1p^E312K^ and Kes1p W317A (Kes1p^W317A^) using the photolabeling assay described above. In neither case could we detect binding of full-length mutant protein to \[^3^H\]BZDC-PI(4,5)P~2~ ([Fig. 4](#fig4){ref-type="fig"} A) or to \[^3^H\]BZDC-IP~3~ (unpublished data). In vivo complementation experiments reveal that Kes1p^E312K^ and Kes1p^W317A^, while stable proteins in yeast, are nonfunctional (unpublished data).

###### 

**Kes1p PH domain mutations and PIP binding.** (A) Mutations in Kes1p PH domain compromise PIP binding. Photoaffinity-labeling assays were performed with mutant Kes1ps using \[^3^H\]BZDC-PI(4,5)P~2~ as photo-probe. Covalent Kes1p--photo-probe adducts were resolved by SDS-PAGE and visualized by autoradiography. Kes1p^E312K^ and full-length Kes1p^W317A^ fail to bind \[^3^H\]BZDC-PI(4,5)P~2~. A proteolytic breakdown product of Kes1p^W317A^ (Kes1p^W317A\*^) regains PIP binding competence. (B) MALDI-TOF mass spectrometry of Kes1p^W317A^ and Kes1p^W317A\*^. The mass to charge ratios of full-length Kes1p^W317A^ and the Kes1p^W317A\*^ truncation product are shown and the corresponding mass values for each are indicated. Below is an illustration of the Kes1p domain structure where the OSBP and PH domains are designated by the black and gray boxes, respectively. The location of the W~317~A missense substitution within the PH domain is shown by a black bar, and the surrounding wild-type sequence is displayed at bottom (W corresponds to W~317~). The R~314~K~315~ motif that defines the site of proteolysis that generates Kes1p^W317A\*^ is underlined. (C) COOH-terminal Kes1p truncation and PIP binding. Wild-type and mutant forms of Kes1p were genetically truncated after residue K~314~ to generate protein fragments consisting of otherwise wild-type primary sequence (Kes1p^1--314^). GST-tagged versions of Kes1p^1--314^ and Kes1p^E312K\*^ were purified and photolabeled with \[^3^H\]BZDC-IP~3~ in a mixed micelle system in the absence (T) or presence (C) of competitor PI(4,5)P~2~. Both full-length protein and fragments associate with \[^3^H\]BZDC-IP~3~ in a manner that is subject to displacement by PI(4,5)P~2~. (D) COOH-terminal truncation of Kes1p^3E^ fails to rescue PIP binding. GST-tagged Kes1p and Kes1p^3E^, and the corresponding COOH-terminal truncation fragments Kes1p^1--314^ and Kes1p^3E\*^ were purified were photolabeled with \[^3^H\]BZDC-IP~3~ in a mixed micelle system without (T) and with (C) unlabeled PI(4,5)P~2~ competitor. Full-length Kes1p^3E^ fails to bind photo-probe, and this failure is not rescued by Kes1p truncation. (E) PIP binding is essential for Kes1p function in vivo. Centromeric plasmids (YCp) that drive physiological levels of *KES1* or *kes1* ^3E^ expression were transformed into the *kes1* strain CTY159. Transformants were streaked for isolation onto selective minimal media and incubated for 3 d at 26°C or 37°C. Complementation of *kes1* defects is scored by failure of transformants to grow at 37°C.
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Suppression of PIP binding defects by COOH-terminal truncation of Kes1p
-----------------------------------------------------------------------

During the course of the photolabeling experiments, we noted that Kes1p^W317A^ purifies as two species. Both species bind polyclonal anti-Kes1p immunoglobulin, suggesting that the smaller species represents a Kes1p fragment. Surprisingly, this truncated Kes1p (Kes1p^W317A\*^) binds PI(4,5)P~2~, whereas full-length Kes1p^W317A^ does not ([Fig. 4](#fig4){ref-type="fig"} A). Thus, removal of COOH-terminal Kes1p sequences rescues PIP binding by Kes1p^W317A^. Although Kes1p^W317A^ was most prominent in exhibiting this degradation product, preparations of wild-type Kes1p also contain detectable amounts of such a degradation product. This fragment also retains PI(4,5)P~2~ binding capability (unpublished data). Eleven cycles of Edman degradation indicate a sequence of MRGSH~6~M for the Kes1p^W317A\*^ NH~2~ terminus, and this sequence corresponds to the NH~2~-terminal sequence of the His~6~-tagged Kes1p produced in *Escherichia coli* (see Materials and methods). Consequently, the proteolytic event that generates Kes1p^W317A\*^ must remove a COOH-terminal Kes1p domain.

The site of Kes1p proteolysis that generates Kes1p^W317A\*^ was determined. Matrix-assisted laser ionization coupled with time-of-flight mass analysis (MALDI-TOF) analyses yield a mass of 50.663 kD for Kes1p and 36.838 kD for Kes1p^W317A\*^ ([Fig. 4](#fig4){ref-type="fig"} B). These data assigned the Kes1p^W317A\*^ cleavage site to the amide bond of a dibasic motif comprised of Kes1p residues R314 and K315, indicating that Kes1p^W317A\*^ is devoid of the COOH-terminal 120 residues ([Fig. 4](#fig4){ref-type="fig"} B). Interestingly, this cleavage site lies upstream of the W317A substitution. Thus, Kes1p^W317A\*^ represents a proteolytic fragment consisting solely of wild-type Kes1p primary sequence.

To confirm this result, we purified GST-tagged versions of full-length Kes1p and of a protein fragment generated by engineering a Kes1p truncation immediately following residue R314. This truncation product is designated Kes1p(1--314). Consistent with the Kes1p^W317A\*^ data, Kes1p(1--314) binds \[^3^H\]BZDC-IP~3~ with an affinity that is similar to that exhibited by Kes1p itself ([Fig. 4](#fig4){ref-type="fig"} C). We also tested whether the COOH-terminal truncation restores PIP binding to the mutant Kes1p^E312K^. This experiment was of interest for two reasons. First, it tests the allele specificity of the suppression effect elicited by the COOH-terminal truncation mutation. Second, because E312K is retained in the truncated product (unlike the W317A case where the fragment consists of wild-type Kes1p sequence), this experiment tests whether E312K imposes an intrinsic PIP binding defect on Kes1p. Photolabeling data demonstrated that Kes1p^E312K\*^ binds PIPs, whereas full-length Kes1p^E312K^ cannot ([Fig. 4](#fig4){ref-type="fig"} C), indicating deletion of the COOH-terminal 120 Kes1p residues rescues both Kes1p^E312K^ and Kes1p^W317A^ PIP binding defects. Thus, neither E312 nor W317 are intrinsically essential for PIP binding. Rather, COOH-terminal Kes1p sequences inhibit PIP binding by the Kes1p PH domain.

Kes1p mutants intrinsically defective in PIP binding are nonfunctional
----------------------------------------------------------------------

The data indicate that Kes1p^E312K^ and Kes1p^W317A^ exhibit PIP binding defects of a regulatory nature. This complicates conclusions that can be drawn regarding the significance of PIP binding for Kes1p activity from functional analyses of Kes1p^E312K^ and Kes1p^W317A^ alone. To more directly assess the functional significance of PIP binding by Kes1p, we generated Kes1p derivatives with intrinsic defects in PIP binding. Our criteria for such mutants was that these will fail to bind inositide photo-probe, and that these binding failures will not be rescued by COOH-terminal Kes1p truncation.

To generate mutant Kes1p intrinsically defective in PIP binding, we were guided by structural analyses indicating that basic residues in the PH domain variable loop 1 and 2 regions engage inositide headgroups ([@bib29]). We generated a triple mutant Kes1p (Kes1p^3E^) where residues R~236~, K~242~, and K~243~ in the presumed loop 2 region of the Kes1p PH domain were replaced with glutamate (see [Fig. 2](#fig2){ref-type="fig"} B). Kes1p^3E^ fails to bind photo-probe in vitro, and truncation of Kes1p^3E^ distal to residue K~314~ fails to restore PIP binding ([Fig. 4](#fig4){ref-type="fig"} D). Thus, Kes1p^3E^ is intrinsically defective in PIP binding.

The biochemical PIP binding defect translates to loss of Kes1p activity in yeast. Complementation analyses demonstrate that Kes1p^3E^ is nonfunctional in vivo ([Fig. 4](#fig4){ref-type="fig"} D). This defect is manifested even though Kes1p^3E^ is a stable cellular protein that accumulates to steady-state levels that are several-fold greater than those of wild-type Kes1p. Thus, PIP binding is required for Kes1p function in vivo.

Kes1p OSBP domain is nonessential for PIP binding
-------------------------------------------------

To investigate the OSBP motif in detail, we performed alanine-scanning mutagenesis throughout the OSBP domain ([Fig. 5](#fig5){ref-type="fig"} A). Complementation experiments show that Kes1p^HH143/144AA^, Kes1p^K109A^, and Kes1p^E117A^ are nonfunctional in vivo ([Fig. 5](#fig5){ref-type="fig"} B), as are Kes1p^LG115/116AA^ and Kes1p^EQ139/140AA^. All of these proteins are expressed as stable polypeptides in cells (unpublished data). Thus, the OSBP domain is critical for Kes1p function in yeast. Photolabeling experiments demonstrate that OSBP domain mutants avidly bind photo-probe in a manner that is subject to competitive displacement by unlabeled PI(4,5)P~2~ competitor ([Fig. 5](#fig5){ref-type="fig"} A). These data show that the OSBP domain is not required for PI(4,5)P~2~ binding as scored by the photolabeling assay.

###### 

**Analysis of Kes1p OSBP domain mutants.** (A) OSBP domain is not required for PIP binding. The four missense substitutions, as underlined, were engineered into the Kes1p OSBP domain. Two representative proteins, Kes1p^K109A^ and Kes1p^HH143/144AA^, were purified and employed in photolabeling assays using \[^3^H\]BZDC-IP~3~ as photo-probe. These mutant proteins, like Kes1p, retain PIP binding capability. (B) OSBP domain mutants are nonfunctional. Four low copy mutant plasmids were transformed into strain CTY159. Transformants were restreaked onto appropriate media and grow for 2--3 d at 26°C or 37°C. Complementation was assessed as before. (C) PIP binding by Kes1p^S43Y^, Kes1p^E107A^, and Kes1p^LH201/202FN^. The proteins were purified and photolabeled with \[^3^H\]BZDC-IP~3~. These mutant proteins retain PIP binding capability.
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Other mutant forms of Kes1p (S43Y, E107K, LH201/202FNo) harbor unadulterated PH and OSBP domains, yet are nonfunctional in vivo ([Fig. 2](#fig2){ref-type="fig"} A). We find that Kes1p^S43Y^, Kes1p^E107K^, and Kes1p^LH201/202FN^ are all proficient in \[^3^H\]BZDC-PI(4,5)P~2~ binding. Moreover, bound photo-probe is efficiently displaced by the incorporation of excess unlabeled PI(4,5)P~2~ into the photolabeling assay ([Fig. 5](#fig5){ref-type="fig"} C). Competitive displacement assays using purified Kes1p^LH201/202FN^ revealed an IC~50~ of photo-probe displacement of 6.1 μM when PI(4,5)P~2~ was employed as competitor (unpublished data), a value that resembles the IC~50~ of 1.9 μM recorded for wild-type Kes1p ([Fig. 3](#fig3){ref-type="fig"} B). Thus, these mutant Kes1ps bind PI(4,5)P~2~ with affinities similar to that measured for Kes1p (*K* ~D~ = 8.0 μM vs. 2.5 μM, respectively). We conclude that PIP binding is necessary, but insufficient, for Kes1p function in vivo.

Kes1p localizes to Golgi membranes
----------------------------------

Fractionation studies revealed that Kes1p resides in both soluble and membrane-bound pools ([@bib15]). To localize Kes1p more precisely, a YCp(*KES1-YFP*) plasmid was constructed that drives physiological expression levels of a chimera consisting of Kes1p fused via its COOH terminus to the green fluorescent protein (GFP) NH~2~ terminus. This chimera is both stable and functional (unpublished data). To assess Kes1p-GFP distribution, appropriate yeast strains were cultured to midlogarithmic growth phase in minimal medium at 26°C and cells were imaged. As control, we also monitored localization of GFP expressed from an isogenic YCp plasmid carrying a *KES1* promoter cassette. Whereas GFP is distributed diffusely throughout the cytosol, Kes1p-GFP adopts both a diffuse cytosolic location and localization to 3--10 punctate structures dispersed throughout the cytoplasm ([Fig. 6](#fig6){ref-type="fig"}).

![**Kes1p localization.** YCp (*KES1-YFP*) and YEp (*KEX2-RFP*) plasmids were cotransformed into the *kes1* yeast strain CTY159. Liquid cultures of the plasmid-bearing derivative strain were incubated overnight at 26°C with shaking in the appropriate minimal medium. The cultures were then diluted to OD~600~ = 0.2∼0.3, and incubated for an additional 2 to 3 h at 26°C. Cells were gently pelleted and resuspended in ∼50 μl residual medium, 5--8 μl of the suspension was mounted onto glass slides, and the samples were visualized by fluorescence microscopy. The excitatory filters employed for visualization of GFP/YFP and RFP fluorescence were the quinacrine mustard filter (excitation wavelength 495 nm) and rhodamine filter (excitation wavelength 545 nm), respectively. Images were collected by IP Lab 2.0 software and processed with Adobe Photoshop^®^ 5.0. Arrows identify some examples of colocalization.](0201037f6){#fig6}

The punctate component of Kes1p-GFP staining primarily corresponds to a Golgi membrane--associated Kes1-GFP pool. We observed that ∼85% of the Kes1-GFP--positive structures costain with the yeast Golgi complex marker Kex2p-RFP ([Fig. 6](#fig6){ref-type="fig"}). The remaining 15% of the Kes1-GFP--positive structures costain with the fluorescent dye FM4-64 under conditions that trap this lipophilic molecule in early endosomes.

Localization of Kes1p to Golgi membranes requires PIP binding
-------------------------------------------------------------

Previous reports had documented that PIP binding is necessary and sufficient for localization of long OSBPs to target membranes ([@bib30]). To determine whether PIP binding plays the same role in targeting of short OSBPs, representative mutations in the Kes1p PH domain were introduced into a YCp(*KES1-GFP*) expression cassette. Localization of mutant Kes1-GFP proteins was then monitored in living cells by fluorescence microscopy.

As expected, the Kes1p^3E^-GFP chimera exhibit a diffuse intracellular distribution that contrasts with the punctate Golgi region staining recorded for wild-type Kes1p-GFP ([Fig. 7](#fig7){ref-type="fig"} A). Thus, Kes1p^3E^-GFP fails to localize to Golgi membranes in vivo. We also assessed localization of Kes1p^E312K^ and Kes1p^W317A^. These species fail to bind PIPs in vitro as full-length polypeptides, but regain PIP binding activity when the COOH-terminal 120 Kes1p residues are removed. Interestingly, Kes1p^E312K^-GFP and Kes1p^W317A^-GFP exhibit localization profiles similar to those recorded for wild-type Kes1p-GFP, suggesting Kes1p^E312K^ and Kes1p^W317A^ target to Golgi membranes ([Fig. 7](#fig7){ref-type="fig"} A). Thus, unlike the PIP-binding defective Kes1p^3E^, Kes1p^E312K^ and Kes1p^W317A^ are apparently subject to regulatory compensation that exposes their PIP binding activities in the appropriate in vivo context. Kes1p^E312K^ and Kes1p^W317A^ remain nonfunctional, however.

###### 

**Kes1p targeting to yeast Golgi membranes.** (A) Kes1p localization domains. YCp(*GFP*), YCp(*KES1-GFP*) and mutant YCp(*kes1* ^3E^-GFP), YCp(*kes1* ^E312K^-GFP), YCp(*kes1* ^W317A^-GFP), and YCp(*kes1* ^K109A^-GFP) plasmids were introduced into a *kes1* yeast strain. Fluorescence images were captured at 26°C. The kes1p^3E^-GFP and chimeras exhibit a diffuse cytosolic distribution that mimics that of GFP alone. In these three cases, signal is excluded from vacuoles (the dark circular structures). The wild-type (WT) control Kes1p-GFP and the mutant Kes1p^E312K^-GFP and Kes1p^W317A^-GFP chimeras exhibit typical punctate staining patterns. (B) PI(4)P synthesis and Kes1p localization. A YCp(*KES1::GFP*) plasmid was introduced into wild-type, *pik1-101* ^ts^, *stt4* ^ts^, *sec14-1* ^ts^, and *mss4-2* ^ts^ strains as indicated at right. Fluorescence images were captured at 26°C and after shift to 37°C for 2 h (indicated at top) at an excitation wavelength of 495nm. Pik1p defects exert major defects in Kes1p localization to Golgi membranes, whereas inactivation of Stt4p and Sec14p has more modest effects.
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Defects in PI-4-P synthesis compromise Kes1p localization to Golgi membranes
----------------------------------------------------------------------------

To test whether defects in PIP synthesis release of Kes1p from Golgi membranes, we expressed Kes1p-GFP in strains carrying *ts* alleles of each of the two known yeast phosphatidylinositol (PI) 4-kinases (Pik1p and Stt4p). As described above, Kes1p-GFP adopts a characteristic punctate localization pattern in wild-type cells incubated at 26°C ([Fig. 7](#fig7){ref-type="fig"} B). By contrast, Kes1p-GFP redistributes from Golgi membranes to the cytosol in the *pik1-101* ^ts^ mutant incubated at either 26°C or 37°C ([Fig. 7](#fig7){ref-type="fig"} B). Thus, Pik1p, which localizes to Golgi membranes ([@bib45]), catalyzes synthesis of a PIP pool, PI(4)P and/or PI(4,5)P~2~, that is required for localization of Kes1p to yeast Golgi membranes. Kes1p mislocalization in the *pik1-101* ^ts^ strain at 26°C indicates that this *pik1* ^ts^ allele is quite defective even at permissive temperatures, a result in accord with the potent synthetic lethalities exhibited by *pik1-101* ^ts^ when combined with a number of other mutations that compromise secretory pathway function ([@bib45]). By contrast, inactivation of Stt4p at 37°C results in some mislocalization of Kes1p to cytosol at 26°C ([Fig. 7](#fig7){ref-type="fig"} B). Relative to *pik1-101* ^ts^, these effects are modest. Thus, Stt4p-derived PIPs play more minor roles in Kes1p targeting to Golgi membranes than do Pik1p-derived PIPs. To distinguish whether PI(4)P or PI(4,5)P~2~ is a Golgi region ligand for Kes1p, we assessed Kes1p-GFP localization in mutants inactivated for Mss4p, the yeast PI(4)P 5-kinase. Even long shift of *mss4-2* ^ts^ mutants to restrictive temperatures (37°C) fails to compromise Kes1p-GFP association with Golgi membranes ([Fig. 7](#fig7){ref-type="fig"} B).

We also tested whether inactivation of the Golgi complex--associated Sec14p affects Kes1p localization. Sec14p stimulates PIP synthesis in a variety of in vitro systems ([@bib21]; [@bib12]; [@bib25]). Moreover, Sec14p stimulates PI(4)P synthesis in yeast ([@bib20]; [@bib36]). Kes1p localization is not compromised in *sec14-1* ^ts^ strains at 26°C. Shift of the *sec14-1* ^ts^ strain to 37°C for 30 min reduces, but does not abolish, Kes1p association with Golgi membranes ([Fig. 7](#fig7){ref-type="fig"} B).

Localization of Kes1p to Golgi membranes requires a functional OSBP domain
--------------------------------------------------------------------------

Analyses of mutants compromised for OSBP domain function demonstrate that an intact OSBP domain is also essential for proper localization of Kes1p-GFP in living cells. Imaging experiments show that the Kes1p^K109A^-GFP chimera adopts a diffuse cytosolic distribution with no visible concentration in punctate structures ([Fig. 7](#fig7){ref-type="fig"} C). Kes1p-GFP chimeras with mutant OSBP domains (i.e., Kes1p^HH143/144AA^-GFP, Kes1p^LG115/116AA^-GFP, and Kes1p^VS141/142AA^-GFP) also exhibit exclusively cytosolic staining profiles (unpublished data). Of interest is the allele specificity that underlies these localization defects. E107K represents a missense substitution at a position only two residues upstream of K109A. Yet, Kes1p^E107K^ does not mistarget to the cytosol (unpublished data), whereas Kes1p^K109A^ does. Finally, mutations that release Kes1p-GFP to the cytosol are not limited to the OSBP domain. For example, LH201/202FN also has this effect (unpublished data). We conclude the region bounded by Kes1p residues 109--202 is critical for the Kes1p localization to membranes, and that the OSBP domain is an essential component of this membrane targeting information.

Because Kes1ps with defective OSBP domains bind PIPs, we tested whether this domain contributes to Golgi region targeting by binding another lipid. To this end, we determined whether the phospholipase D (PLD)-driven accumulation of PA that accompanies Sec14p inactivation is required for Kes1p localization to the yeast Golgi region. This effort was motivated by the weak binding of Kes1p to PA monomers (see above). PLD deficiency markedly reduces Golgi region/endosomal PA levels in Sec14p-deficient yeast ([@bib31]), but has no effect on Kes1p localization in Sec14p-deficient strains (unpublished data). In accord with our previous findings that the involvement of Kes1p in yeast Golgi region function is independent of metabolic flux through the yeast sterol biosynthetic pathway ([@bib15]), we also find that mutations compromising sterol biosynthesis (e.g., *erg6*) do not result in obvious mislocalization of Kes1p from Golgi membranes (unpublished data).

Relationship between magnitude of Kes1p overexpression required for compromise of "bypass Sec14p" and PI(4)P levels
-------------------------------------------------------------------------------------------------------------------

Since genetic data indicate Kes1p antagonizes activity of the Sec14p pathway for Golgi region secretory function, we overexpressed Kes1p in "bypass Sec14p" mutant strains. In agreement with previous demonstrations ([@bib15]), all mechanisms for "bypass Sec14p" are sensitive to increased *KES1* gene dosage ([Fig. 8](#fig8){ref-type="fig"} A). Kes1p is unique in this respect. Increased dosage of structural genes for enzymes of the CDP-choline pathway (i.e., *CKI1*, *PCT1*, and *CPT1*) or the Sac1p PIP phosphatase (*SAC1*) have no effect on nonallelic mechanisms for "bypass Sec14p" (unpublished data). Although modest overproduction of Kes1p compromises all other mechanisms of "bypass Sec14p", robust overexpression of Kes1p is required for this effect in *sac1* mutants ([Fig. 8](#fig8){ref-type="fig"} A).

###### 

**Kes1p dosage and "bypass Sec14p".** (A) Distinct sensitivities of different mechanisms for "bypass Sec14p" to increased Kes1p dosages. Kes1p was modestly overexpressed by introduction of YCp (*KES1*), or highly overexpressed by introduction of YEp(*PPGK:: KES1*), which drives Kes1p expression from a powerful *PGK* promoter (see Materials and methods). All mechanisms of "bypass Sec14p" except that mediated by *sac1* are sensitive to modest increases (two- to threefold) in Kes1p levels. A high degree (∼20-fold) of Kes1p is required for compromise of "bypass Sec14p" in *sac1* mutants. (B) Structure of Sac1pΔTM. The first 462 codons of Sac1p, which include the catalytic domain but not the transmembrane domain, were fused to a protein A tag. This construct is designated Sac1pΔTM and its expression is under control of the native *SAC1* promoter. Details of the construction are available from the authors by request. (C) PI(4)P levels as a function of Sac1pΔTM expression. A wild-type *SAC1* strain, a *sac1* mutant strain, and isogenic *sac1* derivatives transformed either with YCp(*sac1* ^Δ^ *^TM^*) or YEp(*sac1* ^Δ^ *^TM^*) were pulse radiolabeled for 20 min at 26°C with \[^32^P\]-orthophosphate (10 μCi/ml), phospholipids were extracted under acidic conditions, lipids were resolved by two-dimensional paper chromatography, and PI(4)P was identified and quantified by phosphorimaging ([@bib39]). PI(4)P is expressed as a percentage of total extractable phospholipid. Relevant strain genotypes are indicated. The various strains incorporated similar amounts of \[^32^P\]-radiolabel into total lipid. Data are expressed as the mean ± standard deviation from at least three independent experiments. (D) Sac1pΔTM expression sensitizes *sac1*-mediated "bypass Sec14p" to Kes1p. Isogenic *sac1* and *sac1*/YEp(*sac1* ^Δ^ *^TM^*) yeast strains were transformed with YCp(*KES1*). Transformants were subsequently isolated and streaked for isolated colonies on selective medium at 37°C. Growth was scored after 48 h of incubation. Relevant genotypes are given.
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Because *sac1* mutants are unique among "bypass Sec14p" mutants in their massive overproduction of PI(4)P ([@bib19]; [@bib39]; [@bib42]), there is a correlation between PI(4)P levels and the magnitude of Kes1p overproduction required to abolish "bypass Sec14p". To investigate whether the Kes1p levels required to abolish "bypass Sec14p" in *sac1* mutants are proportional to PI(4)P levels, we expressed in *sac1* mutants a truncated Sac1p. This truncated Sac1pΔTM contains the PIP phosphatase catalytic domain but lacks the COOH-terminal transmembrane domain ([Fig. 8](#fig8){ref-type="fig"} B). Sac1pΔTM is a partially functional protein as it partially alleviates the derangement of PIP metabolism that characterizes *sac1* mutants ([Fig. 8](#fig8){ref-type="fig"} C). As shown previously, PI(4)P constitutes 17.8 ± 0.8% and 3.6 ± 0.6% of extractable phospholipid in *sac1* mutants and wild-type yeast, respectively ([@bib19]; [@bib39]; [@bib42]). By comparison, PI(4)P levels are markedly reduced to 8.1 ± 1.2% in the *sac1* mutant that expresses Sac1pΔTM from YEp(*sac1* ^Δ^ *^TM^*) ([Fig. 8](#fig8){ref-type="fig"} C). Expression of Sac1pΔTM from a YCp(*sac1* ^Δ^ *^TM^*) vector effects only minor reductions in PI(4)P levels in a *sac1* genetic background (15.3 ± 0.5%).

The reduction in PI(4)P recorded in the YEp(*sac1*Δ*^TM^*) strain corrects the inositol auxotrophy and *cs* growth phenotypes of *sac1* mutants, but fails to ablate *sac1*-mediated "bypass Sec14p" (unpublished data). However, Sac1pΔTM-mediated reduction in PI(4)P levels strongly sensitizes the "bypass Sec14p" phenotype of *sac1* mutants to elevated Kes1p. Whereas large increases in *KES1* dosage are required for compromise of "bypass Sec14p" in *sac1* mutants, modest increases in *KES1* dosage ablate "bypass Sec14p" in *sac1* YEp(*sac1*Δ*^TM^*) strains ([Fig. 8](#fig8){ref-type="fig"} D). Thus, the magnitude of Kes1p overproduction required for compromise of "bypass Sec14p" is proportional to cellular PI(4)P levels.

Kes1p is mislocalized in *sac1* mutants
---------------------------------------

Based on analyses of PI(4)P levels in *sac1* mutants bearing *pik1* ^ts^ and *stt4* ^ts^ mutations, it is clear that the accumulated PI(4)P is predominantly synthesized via the Stt4p PI 4-kinase and not the Pik1p kinase ([@bib34]; [@bib17]). Because Pik1p is the Golgi region--localized PI 4-kinase ([@bib45]) and PI(4)P is likely the physiological ligand for Kes1p, we assessed the localization of Kes1p-GFP in *sac1* mutants. As shown in [Fig. 9](#fig9){ref-type="fig"} A, the intracellular profile of Kes1p-GFP distribution in *sac1* mutants is dramatically different from its normal punctate distribution in wild-type strains. Rather, Kes1p-GFP localizes to a few large patches in *sac1* cells that are frequently located in a juxtanuclear position. This altered Kes1p localization pattern does not reflect abnormal *sac1* Golgi region morphology. Distribution of the Golgi complex marker Kex2p is not altered in *sac1* mutants ([Fig. 9](#fig9){ref-type="fig"} B). Rather, consistent with the significant (if not exclusive) localization of a Sac1p to ER compartments in yeast and mammalian cells ([@bib46]; [@bib34]; [@bib17]), we conclude that Kes1p is mistargeted to what are likely ER membranes in *sac1* mutants. We suggest that Kes1p is mistargeted to ER membrane domains enriched in the PI(4)P that accumulates in these mutants. In support of this idea, the Kes1p PH domain is required for this mislocalization as Kes1p^3E^-GFP retains its cytosolic localization in *sac1* mutants, and fusion of the Sac1p PIP phosphatase catalytic domain to the ER-resident protein Sec61p yields a fully functional Sac1p whose expression complements all *sac1*Δ phenotypes (including the "bypass Sec14p" phenotype \[unpublished data\]).

###### 

**Kes1p mislocalization in *sac1* mutants.** YCp(*KES1-GFP*) and YEp(*KEX2-RFP*) plasmids were transformed into wild-type or isogenic *sac1* yeast. Liquid cultures of the plasmid-bearing derivatives were incubated at 26°C in the appropriate minimal medium. Cells were mounted and visualized by fluorescence microscopy. Kes1p-GFP and Kex2p-RFP profiles are shown in A and B, respectively. Relevant genotypes are indicated at left. Because Kex2p is an integral membrane protein, Nomarski images are shown below the corresponding fluorescence images in B.
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Genetic interactions of *kes1*Δ with *arf1*Δ, *gcs1*Δ, and *pik1-101* ^ts^
--------------------------------------------------------------------------

To further understand how Kes1p functions in yeast, we screened for instructive genetic interactions. The phenotypes associated with Kes1p overproduction in many ways mimic those associated with reduced PLD activity ([@bib48]), suggesting that Kes1p is an inhibitor of PLD in yeast. However, our in vivo experiments indicate PLD activity is not sensitive to high levels of Kes1p (unpublished data). Rather, we observed a linkage between Kes1p function and the yeast ARF cycle. Both *arf1*Δ and *gcs1*Δ alleles abrogate *kes1*Δ-mediated "bypass Sec14p". Although an *sec14-1* ^ts^ mutant cannot grow at 37°C, the *sec14-1* ^ts^ kes1Δ derivative grows at wild-type rates. However, the isogenic *sec14-1* ^ts^ kes1Δ *arf1*Δ and *sec14-1* ^ts^ kes1Δ *gcs1*Δ triple mutants are no longer viable at 37°C ([Fig. 10](#fig10){ref-type="fig"} A). This is not the result of more complex genetic interactions between *kes1*Δ and *arf1*Δ or *gcs1*Δ as introduction of *SEC14* into *sec14-1* ^ts^ kes1Δ *arf1*Δ and *sec14-1* ^ts^ kes1Δ *gcs1*Δ mutants restores viability at 37°C (unpublished data). Gcs1p is an ARFGAP, and it is this biochemical activity that is required for *kes1*-mediated "bypass Sec14p" (Yanagisawa, L., and V.A. Bankaitus, unpublished data).

###### 

**Genetic interactions between *kes1*** *Δ* **, *arf1*** *Δ* **, *gcs1*** *Δ* **, and *pik1--101*^ts^ alleles.** (A) "Bypass Sec14p" in *arf1*Δ strains. Isogenic sets of wild-type (WT), *sec14-1* ^ts^, *sec14-1* ^ts^ kes1Δ, *sec14-1* ^ts^ kes1Δ *arf1*Δ, and *sec14-1* ^ts^ kes1Δ *gcs1*Δ strains were incubated on YPD agar at 26°C or 37°C (a restrictive temperature for *sec14-1* ^ts^ strains) as indicated for 72 h. WT and *sec14-1* ^ts^ strains represent positive and negative growth controls, respectively. The *kes1*Δ allele rescues *sec14-1* ^ts^ lethality at 37°C, and this rescue is abolished by *arf1*Δ and *gcs1*Δ*.* The *arf1*Δ and *gcs1*Δ alleles do not compromise growth of otherwise WT strains at 37°C. (B) Kes1p deficiency partially suppresses growth defects of the *pik1* ^ts^ strain. Each strain was serially diluted from original culture (OD~600~ = 0.6) by 10-, 100-, and 1,000-fold. 3 μl of each dilution was inoculated onto YPD plates, and plates were incubated for 3 d at 26°C and 35°C, respectively.
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Second, we recorded a genetic interaction between *kes1*Δ and a mutation that compromises activity of the Pik1p PI 4-kinase. Yeast strains carrying *pik1-101* ^ts^ grow at 26°C, but not at 35°C or 37°C ([@bib45]; [Fig. 10](#fig10){ref-type="fig"} B). A *kes1*Δ allele clearly improves the growth of *pik1-101* ^ts^ strains at 35°C. In a serial dilution array incubated at 35°C, the *pik1-101* ^ts^ mutant forms colonies only in the undiluted culture inoculum. By contrast, the wild-type control exhibits growth in undiluted and low dilution innocula; i.e., single colonies are scored in regions spotted with aliquots of 1,000-fold dilutions of culture sample. Thus, relative to wild-type, there is an ∼1,000-fold reduction in the viability of *pik1-101* ^ts^ mutants cultured at 35°C. The *kes1*Δ *pik1-101* ^ts^ mutant exhibits a growth profile intermediate between those of wild-type and *pik1-101* ^ts^ strains ([Fig. 10](#fig10){ref-type="fig"} B). Growth was recorded in the inoculum of a 10-fold culture dilution. Thus, *kes1*Δ increases the viability of *pik1-101* ^ts^ mutants some 10-fold at 35°C. This effect is not observed at 37°C, indicating *kes1*Δ exerts only partial suppression of *pik1-101* ^ts^ defects (unpublished data). Nonetheless, this effect is specific by two criteria. First, *kes1*Δ allele has no beneficial effect on the growth of yeast strains defective in Stt4p (unpublished data). Second, no other "bypass Sec14p" alleles (including *sac1* alleles) suppress *pik1-101* ^ts^--associated growth or secretory defects at 35°C (unpublished data).

Genetic interactions of *kes1*Δ with ARF and ARFGAP deficiencies
----------------------------------------------------------------

Kes1p deficiency elicits a "bypass Sec14p" that, like all "bypass Sec14p" phenotypes, requires Gcs1p ARFGAP activity (Yanagisawa, L., and V.A. Bankaitus, unpublished data). Our finding that Kes1p overproduction mimics Gcs1p defects in "bypass Sec14p" mutants further supports the possibility that Kes1p influences regulation of the ARF cycle. Therefore, we tested whether *kes1*Δ suppresses phenotypes associated with Gcs1p or ARF dysfunction.

Sodium fluoride (NaF) sensitivity is associated with defects in the yeast ARF cycle ([@bib49]). Gcs1p-deficient mutants are sensitive to NaF, as are *arf2*Δ strains carrying the *arf1-3* ^ts^ mutation ([@bib49]; [Table I](#tbl1){ref-type="table"}). Based on the results described above, we predicted that Kes1p defects might suppress NaF sensitivity in *gcs1*Δ and *arf1-3 arf2*Δ strains. Although both *gcs1*Δ and *arf1-3 arf2*Δ mutants fail to grow in the presence of 30 and 50 mM NaF, isogenic wild-type strains are NaF resistant ([Table I](#tbl1){ref-type="table"}). However, *kes1*Δ suppresses Gcs1p and ARF1p deficiency in this assay as isogenic *kes1*Δ *gcs1*Δ and *kes1*Δ *arf1-3 arf2*Δ mutants grow when challenged with either 30 or 50 mM NaF ([Table I](#tbl1){ref-type="table"}). Serial dilution experiments indicate that the viability of *gcs1*Δ strains is increased ∼1,000-fold relative by *kes1*Δ.

###### Interactions of *kes1* mutations with perturbations in Arf function

  Genotype                    NaF (0 mM)   NaF (30 mM)   NaF (50 mM)
  --------------------------- ------------ ------------- -------------
  *WT*                        +++          +++           +++
  *sec14-1^ts^*               +++          +++           +++
  *arf1-3 arf2Δ*              ++           −             −
  *arf1-3 arf2Δ kes1Δ*        +++          −             −
  *sec14-1^ts^ gcs1Δ*         ++           −             −
  *sec14-1^ts^ gcs1Δ kes1Δ*   +++          +++           +++
  *pik1-101^ts^*              +++          −             −
  *pik1-101^ts^ kes1Δ*        +++          +++           +++

Genetic interactions between Kes1p and ARF cycle components. KES1 was deleted in gcs1D, arf1-3ts arf2D, and in pik1ts mutants, and strains were grown on YPD agar with indicated NaF concentrations. Wild-type colony size is indicated by +++, smaller colonies by ++, and − indicates no growth at all after 3 d at 26°C. In arf1, gcs1, and pik1 mutants challenged with 50 mM NaF, kes1D affects 103-fold increases in cell viability.

This is not a trivial result of Kes1p defects reducing either the permeability of cells to NaF or the capacity of yeast to accumulate NaF as *kes1*Δ does not increase the threshold of yeast tolerance to NaF. Moreover, *kes1*Δ only modestly influences other phenotypes associated with Gcs1p defects (e.g., sensitivity to hyperosmotic stress). The viability of *gcs1*Δ mutants is reduced ∼10-fold relative to that of isogenic *gcs1*Δ *kes1*Δ mutants (unpublished data). [@bib49] reported that overproduction of any one of several ARFGAPs, including Gcs1p, suppresses NaF sensitivity in *arf1-3 arf2*Δ yeast strains. Thus, *kes1*Δ phenocopies the elevation of ARFGAP levels in *arf1-3 arf2*Δ yeast mutants. Finally, we note that the *pik1-101* ^ts^ mutant resembles *gcs1*Δ and *arf1-3* ^ts^ strains in its NaF sensitive growth, and that NaF sensitivity is relieved by *kes1*Δ ([Table I](#tbl1){ref-type="table"}).

Discussion
==========

Herein, we show Kes1p binds PIPs and this PIP-binding property, in conjunction with its conserved OSBP domain, is essential for Kes1p localization to Golgi membranes. The PIP pool required for Kes1p targeting to Golgi membranes is driven by activity of the Pik1p PI 4-kinase, and Golgi region targeting of Kes1p is required for inhibition of Sec14p-dependent Golgi region function in vivo. We further demonstrate that inactivation of Kes1p not only affects "bypass Sec14p", but that it also elicits a suppression of some phenotypes associated with ARF and ARFGAP dysfunction. We propose that it is through its effects on ARF that Kes1p regulates Sec14p-dependent Golgi membrane secretory function in yeast.

The PIP binding activity resides in what appears to be a Kes1p PH domain. Although the existence of PH domains has been documented for long OSBPs (e.g., OXYB yeast Osh1; [@bib30]), our findings represent the first demonstration that short OSBPs also binds PIPs. Moreover, our data demonstrate that PIP binding, and its role in targeting an OSBP to Golgi membranes, is a functionally important activity in cells. With regard to the binding of Kes1p to other lipids, we failed to detect significant binding of Kes1p to 25-hydroxycholesterol (unpublished data).

One unanticipated result obtained from analysis of mutations in the Kes1p PH domain is our finding that the E~312~K and W~317~A mutations abolish PIP binding in the context of full-length Kes1p, but not when the COOH-terminal 120 Kes1p residues are removed. Thus, E~312~K and W~317~A do not affect PIP binding directly. Rather, these substitutions likely affect Kes1p conformation in such a way that the PH domain is not accessible to PIPs. Consistent with this model, E~312~ and W~317~ do not reside in the predicted PIP binding loops of the Kes1p PH domain, and truncation of the Kes1p COOH terminus does not rescue PIP binding defects associated with mutations in those loops. Because removal of the Kes1p COOH terminus suppresses E~312~K- and W~317~A-associated PIP binding defects, we speculate that the Kes1p COOH terminus interferes with PH domain function by occluding the PIP binding site. This proposal suggests that PIP binding by Kes1p is subject to conformational regulation by posttranslational modification, or by interaction of Kes1p with some other binding partner (either protein or lipid). This concept is supported by our demonstration that the E~312~K and W~317~A substitutions do not abrogate Kes1p targeting to the Golgi complex in vivo, whereas intrinsic Kes1p defects in PIP binding and defects in PIP synthesis by the Pik1p PI-kinase do.

Unlike the case for long OSBPs, PIP binding is insufficient for Kes1p targeting to Golgi membranes. An intact OSBP domain is also required. These data provide the first indication of a function for this signature motif of OSBPs. It remains unclear how the OSBP domain is involved in localization of Kes1p to Golgi membranes. One possibility is that the Kes1p OSBP motif interacts with the Kes1p COOH terminus to expose the PH domain for PIP binding. We do not find compelling evidence in favor of this model. Inactivating mutations in the OSBP domain neither abolish PIP binding by Kes1p, nor do these strongly compromise the affinity of Kes1p binding of PIP monomers in a mixed micelle system. Alternatively, the OSBP domain may increase the avidity of Kes1p for Golgi membranes by binding another Golgi complex--localized ligand. Finally, the OSBP domain may represent an interface for homotypic binding of Kes1p molecules to each other so that the PH domains are configured in a dimeric arrangement where the PIP binding loops of each PH domain unit are exposed on one face of the dimer. This would generate a PIP binding module with a higher affinity for PIP than that exhibited by monomeric Kes1p. However, an increased binding affinity of dimeric Kes1p would not be apparent in the mixed micelle system we have employed to measure Kes1p--PIP interaction.

Although Kes1p plays an important role in Golgi function in yeast ([@bib15]), the in vivo functions of OSBPs in eukaryotic cells remain unresolved. We suggest that Kes1p function somehow interfaces with activity of the yeast ARF cycle. We find that *arf1*Δ and *gcs1*Δ both abrogate *kes1*Δ-mediated "bypass Sec14p", and several other lines of genetic evidence indicate that Kes1p dysfunction mimics elevated ARFGAP function, whereas elevated Kes1p phenocopies reduced ARFGAP function. Thus, Kes1p may act as: (a) an inhibitor of the Gcs1p ARFGAP activity that is required for yeast Sec14p-dependent Golgi complex function (Yanagisawa, L., and V.A. Bankaitus, unpublished data), (b) a novel ARF nucleotide exchange factor, or (c) an activator of an ARF nucleotide exchange factor. In our hands, Kes1p fails to inhibit the ARFGAP activity of Gcs1p in vitro and we have not detected intrinsic ARF nucleotide exchange activity associated with Kes1p (unpublished data).

Our data suggest that Kes1p may regulate ARF function through its effects on PIP synthesis via the Golgi complex--associated Pik1p as evidenced by the demonstration Kes1p defects partially suppress growth defects associated with Pik1p dysfunction. Kes1p may function, directly or indirectly, as a Pik1p inhibitor in vivo. Alternatively, effects of Kes1p on the ARF cycle may influence Pik1p activity. Linkage of Kes1p localization and function to Pik1p-mediated PI(4)P synthesis suggests that PI(4)P is the physiological Kes1p ligand. Although PI(4,5)P~2~ is bound by Kes1p with a 10-fold higher affinity, PI(4)P mass is fourfold greater than that of PI(4,5)P~2~ in yeast. Moreover, defects in PI(4,5)P~2~ synthesis do not compromise Kes1p localization to Golgi membranes, and massive accumulation of PI(4)P in a non-Golgi compartment entices Kes1p from Golgi membranes. The latter result suggests that a component of the mechanism by which *sac1*-mediated PI(4)P accumulation contributes to "bypass Sec14p" is an indirect one that involves Kes1p mistargeting to what is likely the ER. Finally, the data identify Kes1p as a reporter for Pik1p-driven PIP synthesis on yeast Golgi membranes. Thus, Pik1p facilitates the paradoxical recruitment to Golgi membranes of a protein whose dysfunction permits Sec14p-independent secretory function of Golgi membranes.

Materials and methods
=====================

Strains, media, and reagents
----------------------------

Genotypes for yeast strains are listed in [Table II](#tbl2){ref-type="table"}. Media are described elsewhere ([@bib41]), as are *E. coli* and yeast plasmid transformation techniques ([@bib23]). Vector pQE30 was from QIAGEN. HiTrap Ni^+^ chelating columns and glutathione-Sepharose 4B beads were from Amersham Pharmacia Biotech. PI(4,5)P~2~, PI(4)P, and IP~3~ were from CalBiochem. PI(3,4)P~2~ and PI(3,5)P~2~ were from Echelon Research Laboratories. Other lipids were from Avanti Polar Lipids, Inc. Fine chemicals were from Sigma-Aldrich unless specified. Restriction enzymes were purchased from Promega. \[α-^35^S\]-dATP was obtained from Amersham Pharmacia Biotech.

###### Yeast strains and plasmids

                   Genotypes                                                         Source
  ---------------- ----------------------------------------------------------------- ------------
  Strain number                                                                      
  CTY1-1A          *MATa ura3-52 his3*Δ*-200 lys2-801 sec14-1* ^ts^                  [@bib2]
  CTY100           *MATa ura3-52 his3*Δ*-200 lys2-801 sec14-1* ^ts^ *sac1-26* ^cs^   [@bib9]
  CTY159           *MATa ura3-52 his3*Δ*-200 lys2-801 sec14-1* ^ts^ *kes1-1*         This study
  CTY160           *MATa ura3-52 his3*Δ*-200 lys2-801 sec14-1* ^ts^ *cki1-1*         [@bib9]
  CTY182           *MATa ura3-52 his3*Δ*-200 lys2-801 SEC14*                         [@bib2]
  CTY1537          *MATa ura3-52 leu2 pik1-101* ^ts^                                 [@bib35]
  CTY1585          *MATa ura3-52 leu2 pik1-101* ^ts^ *kes1*Δ*::URA3*                 This study
  Plasmid number                                                                     
  pCTY204          YIp *(KES1)*                                                      
  pCTY244          YCp *(KES1)*                                                      
  pCTY574          YCp *(KES1-GFP)*                                                  
                   YEp *(KEX2-RFP)*                                                  
  pRE540           *His* ~6~ *-KES1*                                                 
  pRE682           *GST-KES1*                                                        
  pRE657           *GST-KES1(1--314)*                                                
  pRE665           *GST-GST-PH* domain                                               

Recovery of genomic *kes1* alleles
----------------------------------

An integrative *KES1* plasmid (pCTY204) was restricted at a unique site within the *KES1* promoter with AflII. Linearized plasmid was transformed into *kes1* strains and recombinants at the *KES1* locus were identified. Genomic DNA was prepared from transformants, restricted with ClaI, and ligated at 15°C. Following transformation into *E. coli* DH5α, plasmid DNA was purified and used as template for nucleotide sequencing.

Site-directed mutagenesis
-------------------------

Mutageneses employed QuickChange™ (Stratagene) and confirmed by DNA sequencing analysis ([@bib40]) using the Sequenase version 2.0 kit (Amersham Pharmacia Biotech).

Plasmid construction
--------------------

Details of the various plasmid constructions are included in supplemental materials or are available from the authors by request.

Expression and purification of His~6~-tagged and GST-tagged proteins from *E. coli*
-----------------------------------------------------------------------------------

One liter of Superbroth (12 g tryptone, 24 g yeast extract, 4 g glycerol, 0.17 M KH~2~PO~4~, 0.72 M K~2~HPO~4~, 50 μg/ml ampicillin) was inoculated with 10 ml of an overnight culture of *E. coli* strain KK2186 harboring plasmids expressing His~6~- or GST-tagged proteins. Protein production was induced with isopropyl β-*D*-thiogalactopyranoside (0.5 mM) and, after 3--5 h, cells were harvested by centrifugation. Cells were disrupted by sonication, and Triton X-100 was added (final concentration 0.1% vol/vol). After addition of DNase I (10 μg/ml) and MgCl~2~ (10 mM), lysate was clarified and filtered.

His~6~-tagged proteins were purified by HiTrap Ni-chelating column chromatography (Amersham Pharmacia Biotech) as per the manufacturer\'s instructions.

Peptide sequencing
------------------

Purified proteins were transferred to Immuno-Blot PVDF membranes (Bio-Rad Laboratories) using the semidry Transblot apparatus (Bio-Rad Laboratories). Blotted PVDF membrane were washed with distilled water and stained with Ponceau S. Kes1p species were excised from membranes and subjected to automated NH~2~-terminal Edman degradation.

Mass spectrometry
-----------------

MALDI-TOF mass spectrometry was performed using positive mode on a Voyager Elite unit with delayed extraction technology (PerSeptive Biosystems). Samples were diluted 1:10 with matrix, and 1 μl of the resulting mix was deposited onto a smooth plate. Acceleration voltage was set at 25 kV and 10--50 laser shots were summed. Sinapinic acid (D13, 460-0; Sigma-Aldrich) dissolved in acetonitrile: 0.1% TFA (1:1) was used as matrix. The mass spectrometer was calibrated with bovine serum albumin.

Online supplemental materials
-----------------------------

PIP photolabeling assay. Photolabeling and displacement assays were performed as described previously ([@bib27]). Details are available at <http://www.jcb.org/cgi/content/full/jcb.200201037/DC1> or from the authors by request.
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